Login to Your Account

Clinic Roundup

Tuesday, March 8, 2011
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., began a Phase II trial of VGX-3100, a DNA vaccine for cervical dysplasia and cancer caused by human papilloma virus. The randomized, placebo-controlled, double-blinded study will include 148 adult females with cervical intraepithelial neoplasias who have HPV type 16 or 18 confirmed by biopsy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription